Kynurenic Acid in the Digestive System–-New Facts, New Challenges

International Journal of Tryptophan Research

Volumn 6, Issue , 2013, Pages

  Turski, Michal P ^a   Turska, Monika ^b   Paluszkiewicz, Piotr ^b   Parada Turska, Jolanta ^b   Oxenkrug, Gregory F ^c  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

digestive system; food; herb; kynurenic acid; pathophysiology

Indexed keywords

EID: 84895124008     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S12536     Document Type: Review

References (76)

1. Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012; 13: 465–77.
2. Adams S., Braidy N., Bessede A. et al. The kynurenine pathway in brain tumor pathogenesis. Cancer Res. 2012; 72: 5649–57.
3. Liebig J. Über Kynurensäure. Justus Liebigs Ann Chem. 1853; 86: 125–6.
4. Alt A., Weiss B., Ogden A.M. et al. Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology. 2004; 46: 793–806.
5. Ganong A.H., Cotman C.W. Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus. J Pharmacol Exp Ther. 1986; 236: 293–9.
6. Kemp J.A., Foster A.C., Leeson P.D. et al. 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc Natl Acad Sci USA. 1988; 85: 6547–50.
7. Kessler M., Terramani T., Lynch G., Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem. 1989; 52: 1319–28.
8. Mok M.H., Fricker A.C., Weil A., Kew J.N. Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology. 2009; 57: 242–9.
9. Turski W.A., Nakamura M., Todd W.P., Carpenter B.K., Whetsell W.O. Jr, Schwarcz R. Identification and quantification of kynurenic acid in human brain tissue. Brain Res. 1988; 454: 164–9.
10. Moroni F., Russi P., Lombardi G., Beni M., Carla V. Presence of kynurenic acid in the mammalian brain. J Neurochem. 1988; 51: 177–80.
11. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001; 21: 7463–73.
12. Wang J., Simonavicius N., Wu X. et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006; 281: 22021–8.
13. Albuquerque E.X., Schwarcz R. Kynurenic acid as an antagonist of alpha7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochem Pharmacol. 2013; 85: 1027–32.
14. Szalardy L., Zadori D., Toldi J., Fulop F., Klivenyi P., Vecsei L. Manipulating kynurenic acid levels in the brain—on the edge between neuroprotection and cognitive dysfunction. Curr Top Med Chem. 2012; 12: 1797–806.
15. Moroni F., Cozzi A., Sili M., Mannaioni G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm. 2012; 119: 133–9.
16. Scharfman H.E., Goodman J.H., Schwarcz R. Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro. Amino Acids. 2000; 19: 283–97.
17. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull. 2010; 36: 211–8.
18. Vamos E., Pardutz A., Klivenyi P., Toldi J., Vecsei L. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci. 2009; 283: 21–7.
19. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic Acid: potential in the treatment of psychiatric disorders. CNS Drugs. 2009; 23: 91–101.
20. Hiratsuka C., Fukuwatari T., Shibata K. Fate of dietary tryptophan in young Japanese women. Int J Tryptophan Res. 2012; 5: 33–47.
21. Zhao J., Chen H., Ni P. et al. Simultaneous determination of urinary tryptophan, tryptophan-related metabolites and creatinine by high performance liquid chromatography with ultraviolet and fluorimetric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879: 2720–5.
22. Crow B., Bishop M., Paliakov E., Norton D., George J., Bralley J.A. Analysis of urinary aromatic acids by liquid chromatography tandem mass spectrometry. Biomed Chromatogr. 2008; 22: 1346–53.
23. Milart P., Sikorski R. Kynurenic acid concentration in blood and urine during normal pregnancy. Ginekol Pol. 1998; 69: 968–73.
24. Furlanetto S., Tognini C., Carpenedo R., La P.E., Pinzauti S. Set-up and validation of an adsorptive stripping voltammetric method for kynurenic acid determination in human urine. J Pharm Biomed Anal. 1998; 18: 67–73.
25. Mawatari K., Iinuma F., Watanabe M. Fluorometric determination of urinary kynurenic acid by flow injection analysis equipped with a “bypass line”. Anal Biochem. 1990; 190: 88–91.
26. Leklem J.E. Quantitative aspects of tryptophan metabolism in humans and other species: a review. Am J Clin Nutr. 1971; 24: 659–72.
27. Parada-Turska J., Rzeski W., Zgrajka W., Majdan M., Kandefer-Szerszen M., Turski W. Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro. Rheumatol Int. 2006; 26: 422–6.
28. Milart P., Urbanska E.M., Turski W.A., Paszkowski T., Sikorski R. Intrapartum levels of endogenous glutamate antagonist—kynurenic acid in amniotic fluid, umbilical and maternal blood. Neurosci Res Com. 1999; 24: 173–8.
29. Kuc D., Zgrajka W., Parada-Turska J., Urbanik-Sypniewska T., Turski W.A. Micromolar concentration of kynurenic acid in rat small intestine. Amino Acids. 2008; 35: 503–5.
30. Pawlak D., Tankiewicz A., Matys T., Buczko W. Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure. J Physiol Pharmacol. 2003; 54: 175–89.
31. Turski M.P., Turska M., Zgrajka W., Kuc D., Turski W.A. Presence of kynurenic acid in food and honeybee products. Amino Acids. 2009; 36: 75–80.
32. Turski M.P., Kaminski P., Zgrajka W., Turska M., Turski W.A. Potato- an important source of nutritional kynurenic acid. Plant Foods Hum Nutr. 2012; 67: 17–23.
33. Glavin G.B., Bose R., Pinsky C. Kynurenic acid protects against gastroduodenal ulceration in mice injected with extracts from poisonous Atlantic shellfish. Prog Neuropsychopharmacol Biol Psychiatry. 1989; 13: 569–72.
34. Glavin G.B., Pinsky C. Kynurenic acid attenuates experimental ulcer formation and basal gastric acid secretion in rats. Res Commun Chem Pathol Pharmacol. 1989; 64: 111–9.
35. Kaszaki J., Palasthy Z., Erczes D. et al. Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs. Neurogastroenterol Motil. 2008; 21: 53–62.
36. Varga G., Erces D., Fazekas B. et al. N-Methyl-d-aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat. Neurogastroenterol Motil. 2010; 22: 217–25.
37. Forrest C.M., Gould S.R., Darlington L.G., Stone T.W. Levels of purine, kynurenine and lipid peroxidation products in patients with inflammatory bowel disease. Adv Exp Med Biol. 2003; 527: 395–400.
38. Clarke G., Fitzgerald P., Cryan J.F., Cassidy E.M., Quigley E.M., Dinan T.G. Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol. 2009; 9: 6.
39. Christmas D.M., Badawy A.A., Hince D. et al. Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome. Nutr Res. 2010; 30: 678–88.
40. Walczak K., Browski D., Langner E. et al. Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells. Scand J Gastroenterol. 2011; 46: 903–12.
41. Walczak K., Turski W.A., Rzeski W. Kynurenic acid enhances expression of p21 Waf1/Cip1 in colon cancer HT-29 cells. Pharmacol Rep. 2012; 64: 745–50.
42. Han Q., Fang J., Li J. Kynurenine aminotransferase and glutamine transaminase K of Escherichia coli: identity with aspartate aminotransferase. Biochem J. 2001; 360: 617–23.
43. Dolecka J., Urbanik-Sypniewska T., Skrzydlo-Radomanska B., Parada-Turska J. Effect of kynurenic acid on the viability of probiotics in vitro. Pharmacol Rep. 2011; 63: 548–51.
44. Kuc D., Rahnama M., Tomaszewski T. et al. Kynurenic acid in human saliva—does it influence oral microflora? Pharmacol Rep. 2006; 58: 393–8.
45. WHO. Protein and amino acid requirements in human nutrition. Report of a Joint WHO/FAO/UNU Expert Consultation. 2007; http://whqlibdoc.who.int/trs/who_trs_935_eng.pdf.
46. Kaihara M., Price J.M., Takahashi H. The conversion of kynurenic acid to quinaldic acid by humans and rats. J Biol Chem. 1956; 223: 705–8.
47. Turski M.P., Turska M., Zgrajka W., Bartnik M., Kocki T., Turski W.A. Distribution, synthesis, and absorption of kynurenic acid in plants. Planta Med. 2011; 77: 858–64.
48. Luccini E., Musante V., Neri E., Raiteri M., Pittaluga A. N-methyl-D-aspartate autoreceptors respond to low and high agonist concentrations by facilitating, respectively, exocytosis and carrier-mediated release of glutamate in rat hippocampus. J Neurosci Res. 2007; 85: 3657–65.
49. Senggunprai L., Yoshinari K., Yamazoe Y. Inhibitory effects of kynurenic acid, a tryptophan metabolite, and its derivatives on cytosolic sulfotransferases. Biochem J. 2009; 422: 455–62.
50. DiNatale B.C., Murray I.A., Schroeder J.C. et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol Sci. 2010; 115: 89–97.
51. Badolo L., Rasmussen L.M., Hansen H.R., Sveigaard C. Screening of OATP1B1/3 and OCT1 inhibitors in cryopreserved hepatocytes in suspension. Eur J Pharm Sci. 2010; 40: 282–8.
52. Banasik M., Komura H., Shimoyama M., Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem. 1992; 267: 1569–75.
53. ElTahir K.E.H., Bakheet B.M. Kynurenic acid as an additional endogenous anti-aggregatory factor. Saudi Pharmaceut J. 2007; 15: 135–9.
54. Jaen J.C., Laborde E., Bucsh R.A. et al. Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor. J Med Chem. 1995; 38: 4439–45.
55. Jauch D., Urbanska E.M., Guidetti P. et al. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J Neurol Sci. 1995; 130: 39–47.
56. Baran H., Cairns N., Lubec B., Lubec G. Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome. Life Sci. 1996; 58: 1891–9.
57. Miranda A.F., Boegman R.J., Beninger R.J., Jhamandas K. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience. 1997; 78: 967–75.
58. Cannazza G., Chiarugi A., Parenti C., Zanoli P., Baraldi M. Changes in kynurenic, anthranilic, and quinolinic acid concentrations in rat brain tissue during development. Neurochem Res. 2001; 26: 511–4.
59. Erhardt S., Oberg H., Engberg G. Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol. 2001; 363: 21–7.
60. Richter A., Loscher W., Baran H., Gramer M. Increased levels of kynurenic acid in brains of genetically dystonic hamsters. Brain Res Dev Brain Res. 1996; 92: 111–6.
61. Salvati P., Ukmar G., Dho L. et al. Brain concentrations of kynurenic acid after a systemic neuroprotective dose in the gerbil model of global ischemia. Prog Neuropsychopharmacol Biol Psychiatry. 1999; 23: 741–52.
62. Amirkhani A., Heldin E., Markides K.E., Bergquist J. Quantitation of tryptophan, kynurenine and kynurenic acid in human plasma by capillary liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 780: 381–7.
63. Ilzecka J., Kocki T., Stelmasiak Z., Turski W.A. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand. 2003; 107: 412–8.
64. Kepplinger B., Baran H., Kainz A., Ferraz-Leite H., Newcombe J., Kalina P. Age-related increase of kynurenic acid in human cerebrospinal fluid—IgG and beta2-microglobulin changes. Neurosignals. 2005; 14: 126–35.
65. Hartai Z., Klivenyi P., Janaky T., Penke B., Dux L., Vecsei L. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. J Neurol Sci. 2005; 239: 31–5.
66. Urbanska E.M., Luchowski P., Luchowska E. et al. Serum kynurenic acid positively correlates with cardiovascular disease risk factor, homocysteine: a study in stroke patients. Pharmacol Rep. 2006; 58: 507–11.
67. Jauch D.A., Sethy V.H., Weick B.G., Chase T.N., Schwarcz R. Intravenous administration of L-kynurenine to rhesus monkeys: effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid. Neuropharmacology. 1993; 32: 467–72.
68. Moroni F., Russi P., Carla V., Lombardi G. Kynurenic acid is present in the rat brain and its content increases during development and aging processes. Neurosci Lett. 1988; 94: 145–50.
69. Swartz K.J., Matson W.R., MacGarvey U., Ryan E.A., Beal M.F. Measurement of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. Anal Biochem. 1990; 185: 363–76.
70. Rejdak K., Bartosik-Psujek H., Dobosz B. et al. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci Lett. 2002; 331: 63–5.
71. Erhardt S., Schwieler L., Engberg G. Kynurenic acid and schizophrenia. Adv Exp Med Biol. 2003; 527: 155–65.
72. Nilsson L.K., Linderholm K.R., Engberg G. et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res. 2005; 80: 315–22.
73. Yamamoto H., Murakami H., Horiguchi K., Egawa B. Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children. Brain Dev. 1995; 17: 327–9.
74. Paluszkiewicz P., Zgrajka W., Saran T. et al. High concentration of kynurenic acid in bile and pancreatic juice. Amino Acids. 2009; 37: 637–41.
75. Boron W.F., Boulpaep E.L. Medical Physiology: A Cellular And Molecular Approaoch. Philadelphia, PA: Elsevier/Saunders; 2005.
76. Zgrajka W., Turska M., Rajtar G., Majdan M., Parada-Turska J. Kynurenic acid content in antirheumatic herbs. Ann Agric Environ Med. 2013; accepted.